Literature DB >> 15896773

The HIN-200 family: more than interferon-inducible genes?

Louise E A Ludlow1, Ricky W Johnstone, Christopher J P Clarke.   

Abstract

The HIN-200 family was initially grouped together based on their hemopoietic expression, interferon-inducibility, nuclear localization, and characteristic 200 amino-acid domains. In this review, we performed a comprehensive search of genome databases and determined the location of previously characterized and predicted genes within the human, mouse, and rat HIN-200 loci. Several novel proteins were predicted in the mouse and rat. We also discuss recent advances in our understanding of this family of proteins and highlight the most important findings. In addition to a role in interferon biology, there is now good evidence supporting a role for these proteins as regulators of cell proliferation and differentiation. The activity of HIN-200 proteins is not restricted to the hemopoietic system as they are expressed and can function in a variety of other cells and tissues. The importance of HIN-200 proteins in disease now is beginning to be understood as they appear to be involved in autoimmunity and may act as tumor suppressor proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896773     DOI: 10.1016/j.yexcr.2005.03.032

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  71 in total

1.  PYHIN proteins: center stage in DNA sensing.

Authors:  Delphine Goubau; Jan Rehwinkel; Caetano Reis e Sousa
Journal:  Nat Immunol       Date:  2010-11       Impact factor: 25.606

Review 2.  Subversion of innate immune signaling through molecular mimicry.

Authors:  Tsan Sam Xiao
Journal:  J Clin Immunol       Date:  2010-06-30       Impact factor: 8.317

3.  Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.

Authors:  Edgar D Charles; Claudia Brunetti; Svetlana Marukian; Kimberly D Ritola; Andrew H Talal; Kristen Marks; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2011-03-18       Impact factor: 22.113

4.  Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

Authors:  Abel Torres; Leslie Storey; Makala Anders; Richard L Miller; Barbara J Bulbulian; Jizhong Jin; Shalini Raghavan; James Lee; Herbert B Slade; Woubalem Birmachu
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

5.  LC/MS identification of 12 intracellular cytoskeletal and inflammatory proteins from monocytes adherent on surface-adsorbed fibronectin-derived peptides.

Authors:  Sean T Zuckerman; Weiyuan John Kao
Journal:  J Biomed Mater Res A       Date:  2008-05       Impact factor: 4.396

Review 6.  Interferon-inducible Ifi200-family genes in systemic lupus erythematosus.

Authors:  Divaker Choubey; Ravichandran Panchanathan
Journal:  Immunol Lett       Date:  2008-07-01       Impact factor: 3.685

7.  Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes.

Authors:  Karen E Johnson; Leela Chikoti; Bala Chandran
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

8.  Structure of the absent in melanoma 2 (AIM2) pyrin domain provides insights into the mechanisms of AIM2 autoinhibition and inflammasome assembly.

Authors:  Tengchuan Jin; Andrew Perry; Patrick Smith; Jiansheng Jiang; T Sam Xiao
Journal:  J Biol Chem       Date:  2013-03-25       Impact factor: 5.157

9.  p204 protein overcomes the inhibition of core binding factor alpha-1-mediated osteogenic differentiation by Id helix-loop-helix proteins.

Authors:  Yi Luan; Xiu-Ping Yu; Ning Yang; Sally Frenkel; Lin Chen; Chuan-Ju Liu
Journal:  Mol Biol Cell       Date:  2008-02-20       Impact factor: 4.138

10.  Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein M013.

Authors:  Masmudur M Rahman; Mohamed R Mohamed; Manbok Kim; Sherin Smallwood; Grant McFadden
Journal:  PLoS Pathog       Date:  2009-10-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.